文献速递免疫规划

恶性疟原虫MSP2与PFF0165c非结构化片段重组融合疫苗的免疫原性

Immunogenicity of a recombinant fusion construct composed of intrinsically unstructured, low polymorphic segments derived from merozoite surface protein 2 and trophozoite exported protein 1.
PubMed 文献 · Vaccine · 2019-07-26

研究将来源于恶性疟原虫裂殖子表面蛋白2(MSP2)和PFF0165c蛋白的三个非结构化、低多态性片段重组为单一融合DNA疫苗(FusN),在流行区志愿者血清中比较其抗原性,并在三种小鼠品系中与三抗原混合物比较免疫原性,同时用亲和纯化人抗体进行抗体依赖性细胞抑制和裂殖子调理试验。结果显示FusN的抗原/免疫原性等于或优于单用或混合片段,且其抗体应答与保护关联更强。

要点

  • FusN融合蛋白的抗原性和免疫原性等于或优于单个片段或三片段混合物。
  • FusN抗体应答与疟疾感染保护的关联强于单个片段。
  • 单一构建体可大幅降低GMP产品制造与开发成本。

核心结论

  • 重组融合产品FusN作为疫苗的抗原/免疫原性等于或优于单独或混合使用的片段,且其抗体应答与保护关联更强。
  • 使用单一构建体可大幅降低GMP产品制造和开发成本。

研究设计与样本

  • 研究在流行区志愿者血清中比较FusN与单个抗原的抗原性。
  • 在三种小鼠品系中比较FusN与三抗原混合物的免疫原性。
  • 用亲和纯化的人抗原特异性抗体进行抗体依赖性细胞抑制和裂殖子调理试验。
  • 测定抗原特异性抗体应答及其与疟疾感染保护的关联。

主要发现

  • FusN的抗原/免疫原性等于或优于单独或混合使用的片段。
  • FusN的抗体应答与保护的关联强于单个片段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To overcome the extensive polymorphism found in human Plasmodium antigens and to avoid the lengthy characterization of their 3 dimensional structure and subsequent production of the native proteins we have been concentrated in large unstructured, non-or low-polymorphic fragments present in the blood stage of P. falciparum. Three fragments derived from the 2 family-specific and constant regions of merozoite surface protein (MSP2) and PFF0165c protein were previously selected for evaluation as potential single vaccine candidates. In order to increase and optimize their potential efficacy against P. falciparum infection the 3 antigens were combined in a single DNA recombinant product (FusN) and compared its antigenicity with that of single antigens in sera of volunteers living in endemic countries. Immunogenicity of the FusN was then compared with that of the mixture of 3 antigens in 3 strains of mice. Antigen specific, affinity purified human antibodies were then tested in antibody dependent cellular inhibition and merozoite opsonization assays. In addition, the antigen specific antibody response and its association with protection from malaria infection were determined. The data collected indicate that the recombinant product is an equal or better antigen /immunogen than fragments used either alone or as a mixture for vaccination in combination with adjuvant. In addition, antibody response to FusN shows a stronger association with protection than single fragments. The use of a single construct as vaccine would drastically reduce the cost of manufacturing and development of the GMP product.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tiendrebeogo RW, Spallek R, Oehlmann W, et al. Immunogenicity of a recombinant fusion construct composed of intrinsically unstructured, low polymorphic segments derived from merozoite surface protein 2 and trophozoite exported protein 1. Vaccine. 2019. PMID: 31358409. doi:10.1016/j.vaccine.2019.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。